©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 7, 2019; 25(29): 3842-3848
Published online Aug 7, 2019. doi: 10.3748/wjg.v25.i29.3842
Published online Aug 7, 2019. doi: 10.3748/wjg.v25.i29.3842
Hepatocellular carcinoma and metabolic syndrome: The times are changing and so should we
Georgios Tsoulfas, Department of Surgery, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece
Author contributions: Tsoulfas G interpreted the literature and wrote the manuscript.
Conflict-of-interest statement: Georgios Tsoulfas reports no conflict of interest.
Corresponding author: Georgios Tsoulfas, FACS, FICS, MD, PhD, Associate Professor, Department of Surgery, Aristotle University of Thessaloniki, University Campus, Thessaloniki 54124, Greece. tsoulfasg@auth.gr
Telephone: +30-697189190 Fax: +30-2310-3320222
Received: April 28, 2019
Peer-review started: April 28, 2019
First decision: May 24, 2019
Revised: June 3, 2019
Accepted: June 25, 2019
Article in press: June 26, 2019
Published online: August 7, 2019
Processing time: 102 Days and 19.6 Hours
Peer-review started: April 28, 2019
First decision: May 24, 2019
Revised: June 3, 2019
Accepted: June 25, 2019
Article in press: June 26, 2019
Published online: August 7, 2019
Processing time: 102 Days and 19.6 Hours
Core Tip
Core tip: There is a changing landscape whereby metabolic syndrome and non-alcoholic fatty liver disease and non-alcoholic steatohepatitis have replaced hepatitis viral infections and alcohol as the predominant causes of cirrhosis and hepatocellular carcinoma (HCC) on the global scale. As such, we need to change the treatment focus and address metabolic syndrome and its elements in an effort to intervene more timely in the development of cirrhosis and HCC.